Thymic carcinomas: Clinicopathologic study of 37 cases from a single institution

Virchows Archiv

Volumn 462, Issue 3, 2013, Pages 307-313

  Thomas De Montpréville, Vincent ^a   Ghigna, Maria Rosa ^a   Lacroix, Ludovic ^b   Besse, Benjamin ^b   Broet, Philippe ^c   Dartevelle, Philippe ^a   Fadel, Élie ^a   Dorfmuller, Peter ^a  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

c Kit mutation; Pathology; Staging system; Surgical treatment; Thymic carcinoid tumor; Thymic squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD5 ANTIGEN; STEM CELL FACTOR RECEPTOR;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CLINICAL ARTICLE; CUSHING SYNDROME; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; ONCOGENE C KIT; OVERALL SURVIVAL; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THYMOMA; THYMUS CANCER; UNDIFFERENTIATED CARCINOMA; CARCINOMA; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; CARCINOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-KIT; THYMUS NEOPLASMS;

MLCS; MLOWN;

EID: 84876078071     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1371-y     Document Type: Article

References (31)

1. Travis D, Brambilla E, Müller-Hermelink K, Harris CC (2004) Tumours of the thymus. In: World Health Organization Classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. International Agency for Research on Cancer (IARC), Lyon
2. Venuta F, Anile M, Diso D, Vitolo D, Rendina EA, De Giacomo T et al (2010) Thymoma and thymic carcinoma. Eur J Cardiothorac Surg 37:13-25
3. Thomas de Montpréville V (2010) Thymomes et carcinomes thymiques. Rev Fr Mal Resp 27:1281-1287
4. Huang J, Rizk NP, Travis WD, Riely GJ, Park BJ, Bains MS et al (2009) Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg 138:26-31
5. Pan CC, Chen PCH, Wang LS, Lee JY, Chiang H (2003) Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 43:165-172
6. Strobel P, Hohenberger P, Marx A (2010) Thymoma and thymic carcinoma. Molecular pathology and targeted therapy. J Thorac Oncol 5:S286-S290
7. Kuhn E, Wistuba II (2008) Molecular pathology of thymic epithelial neoplasms. Hematol Oncol Clin N Am 22:443-455
8. Hirose Y, Kondo K, Takizawa H, Nagao T, Nakagawa Y, Fujino H et al (2009) Aberrant methylation of tumour-related genes in thymic epithelial tumours. Lung Cancer 64:155-159
9. Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C (2011) The Masaoka-Koga stage classification for thymic malignancies. Clarification and definition of terms. J Thorac Oncol 6:S1710-S1716
10. Kondo K (2010) Tumor-node metastasis staging system for thymic epithelial tumors. J Thorac Oncol 5:S352-S356
11. Weissferdt A, Moran CA (2012) Thymic carcinoma, part 2: a clinicopathologic correlation of 33 cases with a proposed staging system. Am J Clin Pathol 138:115-121
12. Tiffet O, Nicholson AG, Ladas G, Sheppard MN, Goldstraw P (2003) A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. Chest 124:141-146
13. Kuo TT, Chan JKC (1998) Thymic carcinoma arising in thymoma is associated with alteration in immunohistochemical profile. Am J Surg Pathol 22:1474-1481
14. Beck F, Guignard R, Richard JB, Wilquin JL, Peretti-Watel P (2011) Augmentation récente du tabagisme en France: principaux résultats du baromètre santé, France, 2010. BEH Institut de Veille Sanitaire 20-21:230-233. http://www.invs.sante.fr/Publications-et-outils/BEH-Bulletin- epidemiologique-hebdomadaire. Accessed 23 Oct 2012
15. Magois E, Guigay J, Saint Blancard P, Margery J, Milleron B, Lher P et al (2008) Multimodal treatment of thymic carcinoma: report of nine cases. Lung Cancer 59:126-132
16. Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S et al (2008) Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 3:265-269
17. Hosaka Y, Tsuchida M, Toyabe S, Umezu H, Eimoto T, Hayashi J (2010) Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg 89:912-917
18. Chalabreysse L, Etienne-Mastroianni B, Adeleine P, Cordier JF, Greenland T, Thivolet-Bejui F (2004) Thymic carcinoma: a clinicopathological study of 19 cases. Histopathology 44:367-374
19. Liu HC, Hsu WH, Chen YJ, Chan YJ, Wu YC, Huang BS et al (2002) Primary thymic carcinoma. Ann Thorac Surg 73:1076-1081
20. Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Chung KY (2009) Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution. Eur J Cardiovasc Thorac Surg 36:159-163
21. Kawaguchi K, Usami N, Okasaka T, Yokoi K (2011) Multiple thymic carcinoids. Ann Thorac Surg 91:1973-1975
22. Ogawa K, Toita T, Uno T, Fuwa N, Kakinohana Y, Kamata M et al (2002) Treatment and prognosis of thymic carcinoma. A retrospective analysis of 40 cases. Cancer 94:3115-3119
23. Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, Tsuchiya R (2005) Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 128:140-144
24. Pan CC, Chen PCH, Chiang H (2004) KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202:375-381
25. Tsuchida M, Umezu H, Hashimoto T, Shinohara H, Koike T, Hosaka Y et al (2008) Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 62:321-325
26. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL (2004) The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors. A study of 96 cases using a single-source antibody with review of the literature. Arch Pathol Lab Med 128:538-543
27. Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H et al (2008) Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 62:316-320
28. Girard N (2010) Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 5:S291-S295
29. Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y et al (2011) MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchows Arch 458:615-620
30. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746-3753
31. Suster S, Moran CA (1995) Thymic carcinoid with prominent mucinous stroma. Report of a distinctive morphologic variant of thymic neuroendocrine neoplasm. Am J Surg Pathol 19:1277-1285